Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma

By sjmartinez • May 29, 2025

Finn RS, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Cheng AL, Galle PR, Kaneko S, Kumada H, Kamble S, Norquist JM, Mody K, Wang A, Dubrovsky L, Llovet JM. Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma. ESMO Open. 2025 May 27;10(6):105065. doi: 10.1016/j.esmoop.2025.105065. Epub ahead of print. PMID: 40435872.

Tags: health-related quality of life, Hematology/Oncology, Hepatocellular carcinoma, lenvatinib, pembrolizumab, Publications

Related Posts

Analyses of adverse events and patient-reported outcomes with the toxicity index in cancer clinical trials

Gresham G, Henry NL, Bandos H, Calsavara VF, Cecchini RS, Diniz MA, Hays RD, Luu M, Kim S, Rogatko A, Yothers G, Ganz PA, Tighiouart[...]

Anti-VEGF neutralizing antibody delays osteomucosal healing by reducing collagen formation in mice

Bae EB, Kim MY, Ji S, Cho IW, Kim SY, Esmaeili M, Baik SS, Kim S, Tetradis S, Park NH, Gwack Y, Kim RH. Anti-VEGF[...]

Collagen-binding IL-12-armoured STEAP1 CAR-T cells reduce toxicity and treat prostate cancer in mouse models

Sasaki K, Bhatia V, Asano Y, Bakhtiari J, Kaur P, Wang C, Matsuo T, Dubois O, Chiu PC, Gun D, Singh C, Panagi I, Noblecourt[...]